Oihane Pikatza-Menoio

Ms. Oihane Pikatza-Menoio

PhD Candidate at the University of the Basque Country, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
OPOihane Pikatza-Menoio
Oihane Pikatza-Menoio
AEAmaia Elicegui
Amaia Elicegui
XBXabier Bengoetxea
Xabier Bengoetxea
NNNeia Naldaiz-Gastesi
Neia Naldaiz-Gastesi
AAAdolfo López de Munain Arregui
Adolfo López de Munain Arregui
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that leads to progressive degeneration of motor neurons (MNs) and severe muscle atrophy without effective treatment. Most research on ALS has been focused on the study of MNs and supporting cells of the central nervous system. Strikingly, the recent observations of pathological changes in muscle occurring before disease onset and independent from MN degeneration have bolstered the interest for the study of muscle tissue as a potential target for delivery of therapies for ALS. Skeletal muscle has just been described as a tissue with an important secretory function that is toxic to MNs in the context of ALS. Moreover, a fine-tuning balance between biosynthetic and atrophic pathways is necessary to induce myogenesis for muscle tissue repair. Compromising this response due to primary metabolic abnormalities in the muscle could trigger defective muscle regeneration and neuromuscular junction restoration, with deleterious consequences for MNs and thereby hastening the development of ALS. However, it remains puzzling how backward signaling from the muscle could impinge on MN death. This review provides a comprehensive analysis on the current state-of-the-art of the role of the skeletal muscle in ALS, highlighting its contribution to the neurodegeneration in ALS through backward-signaling processes as a newly uncovered mechanism for a peripheral etiopathogenesis of the disease.

16 September 2024 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
MZMónica Zufiría
Mónica Zufiría
OPOihane Pikatza-Menoio
Oihane Pikatza-Menoio
MGMaddi Garciandia-Arcelus
Maddi Garciandia-Arcelus
XBXabier Bengoetxea
Xabier Bengoetxea
AJAndrés Jiménez
Andrés Jiménez
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS. We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS-silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs (TBPH or caz) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.

12 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMikel García-Puga
Mikel García-Puga
CHCristina Huergo
Cristina Huergo
AVAinhoa Vidal-Gil
Ainhoa Vidal-Gil
MRMaría Rodríguez-Hidalgo
María Rodríguez-Hidalgo
OPOihane Pikatza-Menoio
Oihane Pikatza-Menoio
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease whose diagnosis often remains delayed. Skeletal muscle is increasingly recognized as an early contributor to ALS pathology. Using lipid imaging mass spectrometry (LIMS) in Tibialis anterior muscle from hSOD1 G93A mice across disease stages, we identified fiber-type-specific and sex-dependent lipid remodeling. Lipid alterations were detected at the presymptomatic stage, preceding motor neuron loss and clinical symptoms. LIMS distinguished fast-twitch oxidative-glycolytic (type IIA) and glycolytic (type IIB/IIX) fibers and revealed their differential vulnerability to disease. Presymptomatic mutant muscles showed loss of physiological lipid signatures alongside disease-specific lipid changes. Although lipid profiles differed between sexes, ALS-associated alterations enabled accurate discrimination of mutant mice before symptom onset. Importantly, similar disease-related lipid changes were detected in serum, enabling accurate classification of presymptomatic animals. These findings establish lipid remodeling as an early ALS event and highlight novel biomarkers with potential for diagnosis and disease monitoring.

17 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MZMónica Zufiría
Mónica Zufiría
OPOihane Pikatza-Menoio
Oihane Pikatza-Menoio
MGMaddi Garciandia-Arcelus
Maddi Garciandia-Arcelus
XBXabier Bengoetxea
Xabier Bengoetxea
AJAndrés Jiménez
Andrés Jiménez
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and FUS . We found a functional impairment of myogenesis that parallels defects of glucose oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of these metabolic and functional features in ALS muscle, via gene expression profiling and biochemical surveys in TDP-43 and FUS silenced muscle progenitors. Strikingly, inhibition of FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS orthologs ( TBPH or caz ) in Drosophila muscle precursor cells resulted in decreased innervation and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially corrected by foxo inhibition, bolstering the potential pharmacological management of muscle intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.

4 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
OPOihane Pikatza-Menoio
Oihane Pikatza-Menoio
HSHh Sutcu
Hh Sutcu
MRMaría Rodríguez-Hidalgo
María Rodríguez-Hidalgo
AEA Elicegui
A Elicegui
AVA Vidal-Gil
A Vidal-Gil
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
TAR DNA-binding protein 43 (TDP-43) dysfunction is a hallmark of amyotrophic lateral sclerosis (ALS) and related disorders, yet its role in skeletal muscle stem cells, the satellite cells (SC), remains incompletely understood. Here, we investigated ALS-associated gain- and loss-of-function TDP-43 mutations together with inducible SC-specific TDP-43 deletion. While TDP-43 Q331K and heterozygous TDP-43 F210I mice displayed normal muscle homeostasis, SC abundance, and regenerative capacity, complete TDP-43 loss caused a marked reduction of the SC pool, particularly in females, and shifted SCs from a CD34 high stem-like state toward a CD34 low primed population. TDP-43-deficient SCs failed to clonally expand, proliferate, and differentiate, resulting in severe regenerative failure following muscle injury. Notably, the SC pool failed to recover after injury and was nearly depleted 30 days post-injury, accompanied by muscle loss, fibrosis and fat infiltration. Transcriptomic analyses revealed activation of stress and aging-associated programs in uninjured TDP-43-deficient SCs, indicating the premature acquisition of an aging-like state. Consistently, chronological aging further exacerbated SC depletion, establishing TDP-43 as a critical regulator of SC stemness, regeneration, and resistance to age-related decline.